Jacob Bell
Lead Reporter | @realjacobbellJacob graduated from the University of Maryland with degrees in journalism and biology. He's previously reported on M&A at TheDeal, politics at McClatchy DC and education research at Education Week. He can also be reached on Signal at realjacobbell.38.
1800 articles by Jacob Bell
-
Bayer wins FDA nod for a new kind of blood thinner
Nov. 9, 2026 -
Argenx to buy peptide platform in potentially billion-dollar deal
Nov. 9, 2026 -
Vertex, ahead of FDA decision, calms fears surrounding kidney drug
Nov. 3, 2026 -
Rapport’s epilepsy drug finds surprising success in bipolar trial
Oct. 20, 2026 -
Iambic CEO on taking an AI drug company public
Oct. 16, 2026 -
Biogen-backed Estuary nabs $93M for kidney disease gene therapy
Oct. 16, 2026 -
Another Paragon spinout goes public through reverse merger
Oct. 13, 2026 -
Parkinson’s cell therapy developer files to go public
Oct. 12, 2026 -
In the hunt for reverse merger targets, Caribou could be prized game
Oct. 8, 2026 -
A Takeda spinout builds case for its Parkinson’s drug
Oct. 7, 2026 -
Sanofi, Regeneron broaden alliance to find their next Dupixent
Oct. 1, 2026 -
UniQure tumbles with latest data for Huntington’s gene therapy
Sept. 29, 2026 -
How J&J paved the way for Compass’ coming psychedelic drug launch
Sept. 21, 2026 -
Skyhawk racks up more support for Huntington’s drug
Sept. 16, 2026 -
This week in charts: RA’s insatiable appetite, Novartis’ big slide and a reverse merger spree
Sept. 11, 2026 -
A booming business on Wall Street would love more biotechs to quietly die
Sept. 10, 2026 -
Novartis RNA drug falls short in rare muscle disease study
Sept. 8, 2026 -
This week in charts: Biotech’s rebound is undeniable
Aug. 28, 2026 -
Michael Polansky has a new, skin-focused biotech. Don’t call it a drug company.
Aug. 27, 2026 -
Amylyx’s bet on a GLP-1 blocker pays off
Aug. 18, 2026 -
EyePoint plummets on pivotal data for main drug
Aug. 17, 2026 -
Psychedelics developer Definium scores more positive data for LSD pill
Aug. 12, 2026 -
Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal
Aug. 10, 2026 -
Latigo IPO raises nearly $350M for pain drug development
Aug. 7, 2026 -
Takeda approval ushers in new wave of sleep drugs
Aug. 6, 2026
